Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
EN
Enanta Pharmaceuticals, Inc
ENTA
Mkt Cap
$323.3M
Volume
184.66K
Next Earnings
November 16th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
EN
ENTA
EN
Enanta Pharmaceuticals, Inc
ENTA
News
·
10 Health Care Stocks With Whale Alerts In Today's Session
Mkt Cap
$334.1M
Volume
184.66K
Next Earnings
November 16th
Chart
Financials
Earnings
News
About
Insider
Filings
10 Health Care Stocks With Whale Alerts In Today's Session
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
Benzinga · Sep 29, 2025
Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults
Enanta Pharmaceuticals released positive Phase 2b trial results for zelicapavir, an oral RSV treatment that demonstrated clinically meaningful symptom reduction in high-risk adult patients, particularly those with chronic conditions.
Benzinga · Sep 29, 2025
12 Health Care Stocks Moving In Monday's Intraday Session
Multiple health care and biotech stocks experienced significant price movements, with some stocks seeing substantial gains while others faced sharp declines during Monday's trading session.
Benzinga · Sep 29, 2025
12 Health Care Stocks Moving In Friday's After-Market Session
Multiple healthcare stocks experienced significant price movements during Friday's after-market trading session, with some companies seeing notable gains while others experienced declines.
Benzinga · Sep 26, 2025
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)
The FDA has approved a label expansion for AbbVie's Mavyret to include the treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis or with compensated cirrhosis. Mavyret has shown a 96% cure rate in an 8-week treatment with mostly mild side effects.
Benzinga · Jun 11, 2025
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
The urticaria pipeline is rapidly expanding, with over 20 leading companies developing 25+ new treatments to address the rising prevalence of the condition. Advances in biologic therapies and a strong R&D pipeline are driving progress, while improved healthcare infrastructure and digital innovations enhance patient access and outcomes.
GlobeNewswire Inc. · Nov 4, 2024
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -16.67% and 3.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 6, 2024
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -33.90% and 20.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · Feb 7, 2024
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research · Jan 5, 2024
The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World
Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World are included in this Analyst Blog.
Zacks Investment Research · Dec 20, 2023
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
EN
ENTA
Enanta Pharmaceuticals, Inc
Buy
Sell
Market
Limit
Soon
ENTA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ENTA yet.
Related Tickers
Earnings